1 BTC
=
- USD
LB Pharmaceuticals Inc Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Market Statistics
Trading Metrics
How to Buy LBRX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy LBRX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
3 articlesFive psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
LB Pharmaceuticals Inc (LBRX) announced a $100 million private placement of common stock and pre-funded warrants at $21.17 per share from institutional investors. The company plans to use proceeds to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, with closing expected on February 6, 2026.
LB Pharmaceuticals announced the appointments of Ellen Rose as Senior Vice President of Corporate Affairs and Lindsay Beaupre as Senior Vice President of People and Culture. Both executives bring extensive experience from leading biopharmaceutical and financial services companies. The appointments come as the company advances LB-102, its novel benzamide candidate, into Phase 3 trials for schizophrenia and Phase 2 trials for bipolar depression.